Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chong Yang

Showing results (551-560 of 560) with videos related to

Pageof 56
Sort By:
You have reached the last page of results.This site can display upto 560 results.
BMJ (Clinical Research Ed.)|February 10, 2026
Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trialRui You, Gui-Qiong Xu, Xi Ding, et al.
The Lancet. Oncology|November 10, 2024
Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trialSai-Lan Liu, Xiao-Yun Li, Jin-Hao Yang, et al.
NEJM Evidence|April 22, 2025
Induction versus Concurrent Chemotherapy for Advanced Nasopharyngeal CarcinomaPei-Yu Huang, Xu-Yin Chen, Xi Ding, et al.
The Lancet. Oncology|June 8, 2023
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trialLi-Ting Liu, Huai Liu, Ying Huang, et al.
JAMA Oncology|July 24, 2020
Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical TrialRui You, You-Ping Liu, Pei-Yu Huang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 1, 2025
[<sup>18</sup>F] Fluorodeoxyglucose positron emission tomography/computed tomography scan and liquid biopsy at 12 weeks posttreatment for surveillance of locoregionally advanced nasopharyngeal carcinomaLi-Ting Liu, Zhen-Chong Yang, Jia-Rui He, et al.
Lancet (London, England)|February 26, 2023
Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trialRui You, You-Ping Liu, Yu-Long Xie, et al.
Cancer Cell|March 19, 2020
Genomic and Transcriptomic Characterization of Natural Killer T Cell LymphomaJie Xiong, Bo-Wen Cui, Nan Wang, et al.
Cancer Communications (London, England)|May 9, 2025
Extranodal diffuse large B-cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT studySi-Yuan Chen, Peng-Peng Xu, Ru Feng, et al.
National Science Review|December 31, 2025
Ultrahigh-energy gamma-ray emission associated with black hole-jet systemsZhen Cao, Felix Aharonian, Yun-Xiang Bai, et al.
Pageof 56

Showing results (551-560 of 560) with videos related to

Sort By:
Pageof 56
You have reached the last page of results.This site can display upto 560 results.
BMJ (Clinical Research Ed.)|February 10, 2026
Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trialRui You, Gui-Qiong Xu, Xi Ding, et al.
The Lancet. Oncology|November 10, 2024
Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trialSai-Lan Liu, Xiao-Yun Li, Jin-Hao Yang, et al.
NEJM Evidence|April 22, 2025
Induction versus Concurrent Chemotherapy for Advanced Nasopharyngeal CarcinomaPei-Yu Huang, Xu-Yin Chen, Xi Ding, et al.
The Lancet. Oncology|June 8, 2023
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trialLi-Ting Liu, Huai Liu, Ying Huang, et al.
JAMA Oncology|July 24, 2020
Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical TrialRui You, You-Ping Liu, Pei-Yu Huang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 1, 2025
[<sup>18</sup>F] Fluorodeoxyglucose positron emission tomography/computed tomography scan and liquid biopsy at 12 weeks posttreatment for surveillance of locoregionally advanced nasopharyngeal carcinomaLi-Ting Liu, Zhen-Chong Yang, Jia-Rui He, et al.
Lancet (London, England)|February 26, 2023
Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trialRui You, You-Ping Liu, Yu-Long Xie, et al.
Cancer Cell|March 19, 2020
Genomic and Transcriptomic Characterization of Natural Killer T Cell LymphomaJie Xiong, Bo-Wen Cui, Nan Wang, et al.
Cancer Communications (London, England)|May 9, 2025
Extranodal diffuse large B-cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT studySi-Yuan Chen, Peng-Peng Xu, Ru Feng, et al.
National Science Review|December 31, 2025
Ultrahigh-energy gamma-ray emission associated with black hole-jet systemsZhen Cao, Felix Aharonian, Yun-Xiang Bai, et al.
Pageof 56